Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Revenue (2022 - 2025)

Historic Revenue for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $314.0 million.

  • Indivior Pharmaceuticals' Revenue rose 228.01% to $314.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 25.36%. This contributed to the annual value of $1.2 billion for FY2024, which is 869.17% up from last year.
  • Per Indivior Pharmaceuticals' latest filing, its Revenue stood at $314.0 million for Q3 2025, which was up 228.01% from $302.0 million recorded in Q2 2025.
  • Indivior Pharmaceuticals' Revenue's 5-year high stood at $314.0 million during Q3 2025, with a 5-year trough of $221.0 million in Q2 2022.
  • Over the past 4 years, Indivior Pharmaceuticals' median Revenue value was $280.0 million (recorded in 2023), while the average stood at $275.5 million.
  • In the last 5 years, Indivior Pharmaceuticals' Revenue surged by 2488.69% in 2023 and then tumbled by 633.8% in 2025.
  • Over the past 4 years, Indivior Pharmaceuticals' Revenue (Quarter) stood at $241.0 million in 2022, then rose by 21.58% to $293.0 million in 2023, then grew by 1.71% to $298.0 million in 2024, then increased by 5.37% to $314.0 million in 2025.
  • Its last three reported values are $314.0 million in Q3 2025, $302.0 million for Q2 2025, and $266.0 million during Q1 2025.